VIP236 (Q3W) + VIP236 (Q2W)
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasms
Conditions
Neoplasms
Trial Timeline
Jan 24, 2023 → Oct 10, 2024
NCT ID
NCT05712889About VIP236 (Q3W) + VIP236 (Q2W)
VIP236 (Q3W) + VIP236 (Q2W) is a phase 1 stage product being developed by Vincerx Pharma for Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT05712889. Target conditions include Neoplasms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05712889 | Phase 1 | Completed |
Competing Products
20 competing products in Neoplasms